Mycophenolate is utilized in mix with different drugs to hold your body back from assaulting and dismissing your relocated organ (like kidney, liver, heart). It has a place with a class of meds called immunosuppressants. It works by debilitating your body's guard framework (safe framework) to assist your body with tolerating the new organ as though it were your own.
Name of the medicinal product
Generic Name: Mycophenolate Mofetil 500 mg Tablets
Brand Name: Gelocept
How to use mycophenolate mofetil oral
Peruse the Medication Guide given by your drug specialist before you begin taking mycophenolate and each time you get a top off. If you have any inquiries, ask your PCP or drug specialist.
Accept this drug by mouth as coordinated by your PCP, ordinarily twice day by day on a vacant stomach, 1 hour prior or 2 hours after suppers.
Gulp down the drug. Try not to pound or bite. On the off chance that you are taking the cases, don't open them before gulping.
If the container breaks apart or if there is dust from the tablets, try not to breathe in the powder or dust, and keep away from direct contact with the skin or eyes. On the off chance that contact happens, wash the influenced skin territory well with cleanser and water or flush your eyes with plain water. Counsel your drug specialist for subtleties.
Since this medication can be retained through the skin and lungs and may hurt an unborn infant, ladies who are pregnant or who may become pregnant ought not to deal with this prescription or inhale the residue from the tablets or powder from the cases.
Continue to take this prescription regardless of whether you feel good. Try not to quit taking mycophenolate without first conversing with your primary care physician.
Certain items may make it harder for your body to assimilate mycophenolate on the off chance that they are taken simultaneously. Try not to take this drug simultaneously as stomach settling agents containing aluminum and additionally magnesium, cholestyramine, colestipol, or without calcium phosphate fasteners (like aluminum items, lanthanum, sevelamer). Ask your drug specialist for additional subtleties.
Try not to change brands or types of mycophenolate except if coordinated by your PCP.
Qualitative and quantitative composition
Each film-coated tablet contains Mycophenolate Mofetil 500 mg.
Presentation: 10 X 10 Tablets
1. Therapeutic indication
Mycophenolate Mofetil is demonstrated in a mix with ciclosporin and corticosteroids for the prophylaxis of intense transfer dismissal in patients accepting allogeneic cardiovascular, renal, or hepatic transfers.
2. Posology and method of administration
Treatment with Mycophenolate Mofetil ought to be started and kept up by properly qualified transfer subject matter experts..
Use in renal transplant:
Adults: Oral Mycophenolate Mofetil ought to be started within 72 hours following transplantation. The suggested portion in renal transfer patients is 1 g controlled twice day by day (2 g day by day portion).
Use in cardiac transplant:
Adults: Oral Mycophenolate Mofetil ought to be started within 5 days following transplantation. The suggested portion in cardiovascular transfer patients is 1.5 g managed twice every day (3 g day by day portion).
Use in hepatic transplant:
Adults: IV Mycophenolate Mofetil ought to be controlled for the initial 4 days following the hepatic transfer, with oral Mycophenolate Mofetil started not long after this endured. The suggested oral portion in hepatic transfer patients is 1.5 g directed twice every day (3 g day by day portion).
Renal impairment: In renal transfer patients with extreme ongoing renal debilitation, outside the prompt post-relocate period, portions more noteworthy than 1 g controlled double a day ought to be kept away from. These patients ought to be carefully observed.
Severe hepatic impairment: No portion changes are required for renal transfer patients with serious hepatic parenchymal illness. No information is accessible for heart relocate patients with serious hepatic parenchymal sickness.
Treatment during rejection episodes: Mycophenolic Acid (MPA) is the dynamic metabolite of Mycophenolate Mofetil. Renal transfer dismissal doesn't prompt changes in MPA pharmacokinetics; measurement decrease or interference of Mycophenolate Mofetil isn't needed. There is no reason for Mycophenolate Mofetil portion change following heart relocate dismissal. No pharmacokinetic information is accessible during hepatic transfer dismissal.
Mycophenolate Mofetil ought not to be given to patients with excessive touchiness to Mycophenolate Mofetil, Mycophenolic corrosive, or any of the excipients. Excessive touchiness responses to Mycophenolate Mofetil have been noticed.
Mycophenolate Mofetil ought not to be given to ladies of childbearing potential who are not utilizing exceptionally compelling contraception.
Mycophenolate Mofetil treatment ought not to be started in ladies of youngster bearing potential without giving a pregnancy test result to preclude unintended use in pregnancy.
Mycophenolate Mofetil ought not to be utilized in pregnancy except if there is no reasonable elective treatment to forestall relocate dismissal.
Mycophenolate Mofetil ought not to be given to ladies who are breastfeeding.
Special warnings and precautions for use
Patients getting immunosuppressive regimens including mixes of the therapeutic item, including Mycophenolate Mofetil, are at an expanded danger of creating lymphomas and different malignancies, especially of the skin.
Blood and immune system
Patients getting Mycophenolate Mofetil ought to be observed for neutropenia, which might be identified with Mycophenolate Mofetil itself, corresponding prescriptions, viral diseases, or a blend of these causes.
Mycophenolate Mofetil ought to be directed with alert in patients with dynamic genuine stomach related framework infection
Aged patients might be at an expanded danger of unfavorable occasions like certain contaminations (counting cytomegalovirus tissue obtrusive illness) and conceivably gastrointestinal drain and pneumonic edema, contrasted and more youthful people.
Patients ought not to give blood during treatment or for at any rate a month and a half after suspension of mycophenolate. Men ought not to give semen during treatment or for 90 days following stopping of mycophenolate.
Powder for concentrate for an answer for imbuement: 2 years.
Reconstitution and weakening:
After reconstitution and weakening, synthetic and physical being used security of answer for imbuement have been exhibited for 24 hours at 20 to 30 °C.
From a microbiological perspective, the item ought to be utilized right away. If not utilized quickly, being used capacity times and conditions before use is the obligation of the client.
Maiden Pharmaceuticals is one of the major manufacturers, suppliers, and exporters of Mycophenolate Mofetil drug in India. We have two manufacturing units for this drug which are WHO-GMP certified. At Maiden Pharmaceuticals manufacturing units use four state-of-the-art ultra-modern technology and the most strict operating procedures and we have earned a name in the market for ourselves for maintaining the highest standards of quality. We have highly skilled, qualified, and experienced technical staff that works to their full potential. Maiden Pharmaceuticals manufacturing plant is fully equipped with cameras and an automated access control system that makes it completely safe. The manufacturing plant has separate entry and exit for the material, team, and service personnel for both processes blocks with proper sanitization.
We also provide third-party manufacturing/ contract manufacturing services for domestic companies/markets. If you are interested in collaborating with us, contact the undersigned.
Phone Number: 9354920720
Email Address: firstname.lastname@example.org
Visit our website for more information www.maidenpharma.com